Trials / Terminated
TerminatedNCT04634825
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- MacroGenics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Enoblituzumab | Anti-B7-H3 antibody |
| BIOLOGICAL | Retifanlimab | Anti-PD-1 antibody |
| BIOLOGICAL | Tebotelimab | PD-1 X LAG-3 bispecific DART molecule |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2022-07-29
- Completion
- 2022-07-29
- First posted
- 2020-11-18
- Last updated
- 2023-12-20
- Results posted
- 2023-12-20
Locations
42 sites across 7 countries: United States, Australia, Bulgaria, Hungary, Poland, Spain, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04634825. Inclusion in this directory is not an endorsement.